Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice Academic Article uri icon

Overview

MeSH Major

  • Aortic Diseases
  • Apolipoproteins E
  • Atherosclerosis
  • Butadienes
  • Hydrocarbons, Fluorinated
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Nitriles
  • Orphan Nuclear Receptors
  • Protein Kinase Inhibitors
  • Sulfonamides

abstract

  • Our study suggests that the combination of mitogen-activated protein kinase kinase 1/2 inhibitor and LXR ligand can function as a novel therapy to synergistically reduce atherosclerosis while eliminating LXR-induced deleterious effects.

publication date

  • April 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1161/ATVBAHA.114.305116

PubMed ID

  • 25810299

Additional Document Info

start page

  • 948

end page

  • 59

volume

  • 35

number

  • 4